These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 18847425)

  • 1. [Advances in diabetes mellitus, diabetic nephropathy, metabolic syndrome and cardio-vascular-renal risk].
    Martínez Castelao A
    Nefrologia; 2008; 28 Suppl 5():79-84. PubMed ID: 18847425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
    Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Trevisan R; Vedovato M; Cavalot F; Cignarelli M; Morano S; Ferrannini E; Pugliese G;
    J Am Geriatr Soc; 2013 Aug; 61(8):1253-61. PubMed ID: 23889588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glitazones in chronic kidney disease: potential and concerns.
    Bolignano D; Zoccali C
    Nutr Metab Cardiovasc Dis; 2012 Mar; 22(3):167-75. PubMed ID: 22364889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic kidney disease: a report from an ADA Consensus Conference.
    Tuttle KR; Bakris GL; Bilous RW; Chiang JL; de Boer IH; Goldstein-Fuchs J; Hirsch IB; Kalantar-Zadeh K; Narva AS; Navaneethan SD; Neumiller JJ; Patel UD; Ratner RE; Whaley-Connell AT; Molitch ME
    Am J Kidney Dis; 2014 Oct; 64(4):510-33. PubMed ID: 25257325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist.
    Martínez-Ramírez HR; Jalomo-Martínez B; Cortés-Sanabria L; Rojas-Campos E; Barragán G; Alfaro G; Cueto-Manzano AM
    Am J Kidney Dis; 2006 Jan; 47(1):78-87. PubMed ID: 16377388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rough road for rosiglitazone.
    Goldfine AB
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Practical management of oral antidiabetics in patients with renal disease].
    Alcazar R; Gonzalez Albarran O; Honorato J; Robles NR; Acha J; de Alvaro F; Fernandez Gallego V; Gomez Garcia P; Lopez de la Torre M; Martinez Castelao A; Romero R
    Nefrologia; 2006; 26(5):538-58. PubMed ID: 17117897
    [No Abstract]   [Full Text] [Related]  

  • 10. [Safety and tolerability of oral hypoglycemic therapies in type 2 diabetes mellitus patients at high cardiovascular risk].
    Ambrosio G; De Ferrari GM; Federici M; Filardi PP
    G Ital Cardiol (Rome); 2017 Jun; 18(6):485-495. PubMed ID: 28631762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current concepts in the management of diabetic nephropathy.
    Waanders F; Visser FW; Gans RO
    Neth J Med; 2013 Nov; 71(9):448-58. PubMed ID: 24218418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Influence of diabetes incidence by ramipril and rosiglitazone: DREAM study (diabetes reduction assessment with ramipril and rosiglitazone medication)].
    Standl E; Nitschmann S
    Internist (Berl); 2007 Oct; 48(10):1173-6. PubMed ID: 17846732
    [No Abstract]   [Full Text] [Related]  

  • 14. Diabetes prevention: still no effective drugs.
    Prescrire Int; 2007 Dec; 16(92):258. PubMed ID: 18095391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of glycemic control on the development of diabetic cardiovascular and kidney disease.
    Saha SA; Tuttle KR
    Cardiol Clin; 2010 Aug; 28(3):497-516. PubMed ID: 20621253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-diabetic renal disease in patients with type 2 diabetes mellitus.
    Prakash J; Sen D; Usha ; Kumar NS
    J Assoc Physicians India; 2001 Apr; 49():415-20. PubMed ID: 11762610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
    Singh S; Loke YK; Furberg CD
    JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.
    Fonarow GC
    Am Heart J; 2004 Oct; 148(4):551-8. PubMed ID: 15459582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Type 2 diabetes mellitus and cardiovascular risk factors: is comprehensive treatment required?].
    Nadal JF; Gutiérrez PC
    Med Clin (Barc); 2013 Sep; 141 Suppl 2():7-13. PubMed ID: 24444518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.